Evolus Inc (NASDAQ:EOLS)
| 7.21 Delayed Data As of Nov 30 |  +0.10 / +1.41%Today’s Change | 5.06 Today|||52-Week Range 14.34 | +10.75% Year-to-Date |
Latest EOLS News | Press Releases
No recent news for Evolus Inc.
Today’s Trading
| Previous close | 7.11 |
| Today’s open | 7.11 |
| Day’s range | 7.00 - 7.32 |
| Volume | 16,282 |
| Average volume (3 months) | 479,215 |
| Market cap | $437.6M |
Data as of 4:01pm ET, 11/30/2022
Growth & Valuation
| Earnings growth (last year) | +80.54% |
| Earnings growth (this year) | +7.16% |
| Earnings growth (next 5 years) | +16.00% |
| Revenue growth (last year) | +76.29% |
| P/E ratio | NM |
| Price/Sales | 3.25 |
| Price/Book | 5.28 |
Competitors
| ---- | ||
| --Tempo Scan Pacific T... | 0.00 | 0.00% |
| KPTIKaryopharm Therapeut... | +0.22 | +4.34% |
| LXRXLexicon Pharmaceutic... | +0.07 | +3.40% |
Data as of 4:01pm ET, 11/30/2022
Financials
| Next reporting date | March 1, 2023 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $99.7M |
| Annual profit (last year) | -$46.8M |
| Net profit margin | -46.96% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Newport Beach, California |
Forecasts
